Best Applied Clinical Trials Podcasts (2025)

1
ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships 2:30

Play Pause

3d ago2:30

2:30

In today’s ACT Brief, we examine how AI is being integrated into administrative workflows at investigative sites, highlight the FDA’s approval of the first gene therapy for adolescents and adults with SMA, and explore strategies for pharmaceutical companies to build high-performing hospital-based clinical trial programs.…

1
E193: The AI Doctor in Your Throat: Real-Time Cancer Detection 31:41

5d ago31:41

31:41

What if artificial intelligence could detect throat cancer instantly — in real time — during a routine exam? In this groundbreaking episode, we speak with Marius Wellenstein, Founder and CEO of WSK Medical, the company behind the world’s first AI-powered endoscopic solution for real-time detection and classification of throat and head & neck cancer…

1
ACT Brief: AI-Driven Pharmacovigilance, Site-Led Digital Investments, and Smarter Multi-Touch Recruitment 2:27

4d ago2:27

2:27

In today’s ACT Brief, we examine how AI and functional service partners are reshaping global pharmacovigilance, look at new data on how investigative sites are investing in and integrating digital solutions, and explore how Trialbee assesses ROI across emerging multi-touch recruitment platforms.By Applied Clinical Trials

1
Pearl of the Week: The Bipolar Blind Spot 13:06

1d ago13:06

13:06

The salient point of this podcast episode is the astonishing statistic that the average delay in accurately diagnosing bipolar disorder is nine years following a patient's initial depressive episode. This revelation underscores a critical issue in mental health care, as such a prolonged period without proper diagnosis can lead to significant distre…

1
Diabetes Core Update – December 2025 33:31

6d ago33:31

33:31

This issue will review: 1. Screening Natriuretic Peptide Levels Predict Heart Failure and Mortality in Individuals with Type 1 and Type 2 Diabetes without Known Heart Failure 2. The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes 3. Continuous Glucose Monitoring Frequency…

1
Why False Positives Are Costing Banks More Than Fraud - with Suvaleena Paul of Bank of America 24:51

4h ago24:51

24:51

Today's guest is Suvaleena Paul, Assistant Vice President and Senior Analyst in Fraud, Innovation, and Analysis at Bank of America. Suvaleena joins Emerj Editorial Director Matthew DeMello to discuss the integration of AI-driven technologies into fraud prevention workflows. She also shares practical insights on improving threat identification speed…

1
Using Artificial Intelligence to Unlock Hidden Insights in Genomic Research - with Dr. Mark Kiel of Genomenon 27:29

7h ago27:29

27:29

Today's guest is Dr. Mark Kiel, Chief Science Officer and Founder at Genomenon. Genomenon is a genomics intelligence company that unlocks real-world evidence from biomedical literature to help pharmaceutical and clinical diagnostics companies inform precision medicine, accelerate patient diagnosis, and guide trial design and label expansion. Mark j…

1
Driving the Systemic Change for AI – with Deborah Golden of Deloitte 39:13

4d ago39:13

39:13

The gap between a promising AI pilot and enterprise-wide, scalable impact remains a critical divide where momentum and resources often stall. Today's guest is Deborah Golden, U.S. Chief Innovation Officer at Deloitte who returns to the show to join Emerj CEO Daniel Faggella to tackle the costly reality of stalled AI initiatives. This conversation m…

1
Bonus Episode: Board Bombs: 3 High-Yield Psychiatric Questions to Prepare You for Your Board Exam 12:03

10d ago12:03

12:03

🔥 Bonus Board Bombs: 3 High-Yield Questions Every PMHNP Must Master Before the Exam Get ready to level up your PMHNP board prep with three ultra-high-yield “Board Bombs” designed to sharpen your clinical reasoning, boost exam confidence, and target the exact concepts PMHNPs tend to miss on test day. In this bonus episode, we break down realistic, e…

1
Strategic AI Adoption for Asset Managers and Enterprise Decision Makers - with Robert Kubin of Amundi 24:33

1h ago24:33

24:33

Today's guest is Robert Kubin, Head of Sales for Central Europe at Amundi. Amundi is a European asset manager, ranked among the top 10 globally by assets under management. It provides savings and investment solutions across active and passive management, in both traditional and real assets. Its offering includes IT tools and services (Amundi Techno…

1
Why Architecture Determines the Future of AI Innovation - with Aaron Levie of Box 37:11

4d ago37:11

37:11

Today's guest is Aaron Levie, CEO of Box. Box provides secure cloud content management and collaboration solutions for enterprises managing unstructured data at scale. Aaron joins Emerj CEO and Head of Research Daniel Faggella to discuss how AI is reshaping enterprise data architecture, from organizing unstructured content to enabling AI-ready work…

1
Special Edition - CVOTs Part 2 34:42

12d ago34:42

34:42

In this special series on The Cardiovascular Outcome Trials our host, Dr. Neil Skolnik will discuss the history and importance of the Cardiovascular Outcome Trials for diabetes medications. In Part 1 we discussed an historical perspective with Dr. Steven Nissen. Today we discuss with Dr. Darren McGuire the incredible evolution of the CVOTs since th…

1
Turning Consumer Goods Data into Real-Time Business Decisions - with Michael Finley of AnswerRocket 26:32

2h ago26:32

26:32

Today's guest is Michael Finley, Chief Technology Officer at AnswerRocket. Founded in 2013, AnswerRocket builds enterprise AI agents delivering measurable outcomes for Fortune 2000 clients across consumer goods, financial services, construction, real estate, and beyond. Finley joins Emerj Editorial Director Matthew DeMello to discuss how enterprise…

1
E192: Building Biotech: What It Takes to Lead a Public Life Sciences Company 29:58

12d ago29:58

29:58

In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers. From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he’s leveraging artificial intelligence, data ana…

1
ACT Brief: Digital Recruitment Strategies, Tremfya’s Long-Term PsA Results, and Agentic AI’s Enterprise Impact 2:36

13d ago2:36

2:36

In today’s ACT Brief, we look at how Trialbee evaluates nontraditional digital platforms for patient recruitment, review new 48-week data from J&J’s APEX trial of Tremfya in psoriatic arthritis, and explore how agentic AI is poised to reshape commercial operations in life sciences.By Applied Clinical Trials

1
Exploring the Diagnostic Challenges in Anxiety: Jean Luc's Journey 25:16

13d ago25:16

25:16

The primary focus of this podcast episode revolves around the intricate relationship between caffeine consumption and its potential psychological ramifications, particularly as illustrated through the case of a mock patient named Jean Luc. Jean Luc presents with a constellation of symptoms including erratic sleep patterns, heart palpitations, and t…

1
Looking at Retail Challenges from a Data Perspective - with Nick Masca of Marks and Spencer 20:10

9h ago20:10

20:10

Today's guest is Nick Masca, Head of Data Science for Growth & Personalisation at Marks and Spencer. Marks and Spencer plc is a prominent British multinational retailer headquartered in London, England, known for offering a wide range of clothing, beauty items, home goods, and food products. Nick joins us on the program to surmise his views on the …

1
ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care 2:17

14d ago2:17

2:17

In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s approval of a first-in-class menin inhibitor for NPM1-mutated AML, and explore new insights on closing biomarker-testing gaps in oncology.By Applied Clinical Trials

1
Solving Hard Industrial Problems with Fast AI Deployment - with Kriti Sharma of IFS Nexus Black 19:50

1d ago19:50

19:50

Today's guest is Kriti Sharma, CEO of IFS Nexus Black. Nexus Black specializes in solving complex operational challenges in asset-intensive environments by bringing AI engineers and domain experts directly to the factory floor, shop floor, and field. Kriti joins Emerj Editorial Director Matthew DeMello to explain how industrial leaders can move fro…

1
Turning Operational Data into AI Ready Assets - with Andrew Deutsch of RR Donnelly and the Fangled Group 30:04

3d ago30:04

30:04

Today's guest is Andrew Deutsch, CEO of the Fangled Group and Director of Operations at RR Donnelley. Fangled Group is a global marketing and sales consultancy specializing in data-driven strategies that accelerate market entry for small to medium-sized manufacturers. Andrew joins Emerj Editorial Director Matthew DeMello to discuss leveraging data …

1
ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results 2:24

17d ago2:24

2:24

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a new partnership enabling automated eSource-to-EDC data transfer, and highlight Gilead’s positive Phase III ARTISTRY-1 trial results in virologically suppressed adults with HIV.By Applied Clinical Trials

1
Why Regulated Industries Must Rethink Copyright and AI - with Roanie Levy of CCC 24:12

9d ago24:12

24:12

Today's guest is Roanie Levy, Licensing and Legal Advisor, CCC. CCC provides collective copyright licensing services for corporate users of copyrighted materials. Roanie joins Emerj Editorial Director Matthew DeMello to break down how generative AI is changing copyright risk management for enterprises — from the impacts of Shadow AI to the realitie…

1
Improving Site Satisfaction Through Better Technology and Collaboration 18:58

17d ago18:58

18:58

Melissa Hutchens, vice president of research & benchmarking at WCG, and Jimmy Garza, senior director of clinical operations at Bayer, discuss findings from the latest WCG CenterWatch Global Site Relationship Survey, revealing a decline in overall site satisfaction. They explore key drivers behind this trend, including technology usability, communic…

1
A Practical Path from Roles to Skills for AI-Ready Teams - with Trish Vassar of Coca-Cola 22:07

5d ago22:07

22:07

Today's guest is Trish Vassar, Vice President of Global Learning & Development, who brings over 20 years of experience in talent management, learning, and leadership development. She joins Emerj Editorial Director Matthew DeMello to explore how enterprise leaders can shift from traditional role-based planning to skills-based workforce strategies po…

1
ACT Brief: AI Decision-Making, Sponsor Oversight Trends, and HHS Label Changes 1:58

19d ago1:58

1:58

In today’s ACT Brief, we look at how artificial intelligence is reshaping drug development decisions across pharma, discuss evolving sponsor oversight in site selection and protocol design, and review the FDA’s decision to update menopausal hormone therapy labels for clarity and safety.By Applied Clinical Trials

1
Turning AI Ambition into Infrastructure Reality – with Julian Tang of BlackRock 17:39

11d ago17:39

17:39

Today's guest is Julian Tang, Chief Operations Officer for the Innovation Office at BlackRock. With extensive experience in financial technology and infrastructure, Julian specializes in integrating AI and data strategies to transform enterprise workflows. Julian joins Emerj Editorial Director Matthew DeMello to explore how leading organizations ar…

1
E191: Quantum Computation In Medicine: The Challenges, What Comes After Large Language Models For Medicine 39:12

19d ago39:12

39:12

In this episode, we explore the future of medicine beyond artificial intelligence with Joseph Geraci — mathematician, medical scientist, and quantum machine learning pioneer. While today’s AI breakthroughs and large language models (LLMs) have transformed diagnostics, data analysis, and drug discovery, quantum computing could completely redefine wh…

1
ACT Brief: Adaptive Trial Designs, Wegovy’s MASH Breakthrough, and Lilly’s Expanding Partnerships 2:46

20d ago2:46

2:46

In today’s ACT Brief, we look at how adaptive trial models are reshaping precision medicine, new data showing Wegovy’s impact on liver health, and Eli Lilly’s latest collaborations advancing genetic and RNA-based therapies.By Applied Clinical Trials

1
PEARL OF THE WEEK: What is the only DSM diagnosis that requires a rating of symptoms? 11:47

20d ago11:47

11:47

Think you know your DSM-5-TR inside and out? In this Pearl of the Week episode, we’re asking a question that stumps even seasoned clinicians: Which DSM-5-TR diagnosis actually requires a validated rating scale to confirm it? Is it: A. Autism Spectrum Disorder — with its structured ADOS and ADI-R interviews? B. ADHD — the classic ASRS and Vanderbilt…

1
Challenges HR Leaders Face in Adopting Enterprise AI - with Raúl Monroig of Bristol Myers Squibb 29:12

7d ago29:12

29:12

Today's guest is Raul Monroig, People Organization Vice President for the Intercon Region at Bristol Myers Squibb. Bristol Myers Squibb manufactures prescription medicines across oncology, hematology, immunology, cardiovascular disease, and neuroscience. With a truly global footprint, the company's research, manufacturing, and commercial presence s…

1
ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers 2:25

21d ago2:25

2:25

In today’s ACT Brief, we explore how AI and tokenized data are improving patient-protocol matching, highlight Caplyta’s new FDA approval for major depressive disorder, and review the FDA’s expansion of its National Priority Voucher program.By Applied Clinical Trials

1
Special Edition: What's Next—An Update on Beta Cell Function 31:09

21d ago31:09

31:09

In this special episode on a Beta Cell Update Dr. Neil Skolnik discusses this emerging area with Dr. Melena Bellin. This special episode is supported by an independent educational grant from Sanofi. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Dir…

1
How to Leverage AI for Skill Verification - with Taylor Sullivan of Workera 19:25

8d ago19:25

19:25

Today's guest is Taylor Sullivan, Head of Product and Assessments at Workera. Workera provides AI-driven skills verification and assessment solutions for organizations. Taylor joins Emerj Editorial Director Matthew DeMello to discuss how organizations can move from skill inferencing to verified, measurable skills, enabling more confident talent dec…

1
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research 2:43

24d ago2:43

2:43

In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from Novo Nordisk’s oral semaglutide program, and review Eli Lilly’s promising Phase II results for a novel amylin receptor agonist.By Applied Clinical Trials

1
Agentic AI and the Strategy Behind Smarter Talent Decisions - with Sachit Kamat of Eightfold AI 24:49

23d ago24:49

24:49

Today's guest is Sachit Kamat, Chief Product Officer at Eightfold AI. Eightfold AI provides a complete AI platform for talent management to help companies find, recruit, and retain workers with the goal of increasing the efficiency and effectiveness of talent operations. Sachit joins Emerj Editorial Director Matthew DeMello to discuss how agentic A…

1
Unmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies

24d ago

—

Guest: Amy McMichael, MD Psoriasis in skin of color is often overlooked because of differences in its presentation. Hear from Dr. Amy McMichael as she explains diagnostic challenges and shares therapeutic strategies for this patient population. Dr. McMichael is a Professor of Dermatology at Wake Forest University School of Medicine in Winston-Salem…

1
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation 2:56

25d ago2:56

2:56

In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class approval for TK2 deficiency, and why strong data foundations are key to realizing AI’s full potential in pharma.By Applied Clinical Trials

1
Scaling GenAI Without Burdening the Data Center - with Greg Ratcliff of Vertiv 24:21

12d ago24:21

24:21

Today's guest is Greg Ratcliff, Chief Innovation Officer at Vertiv. With 30 years of experience leading technology teams and global innovation initiatives, Gregory offers deep expertise in data, IoT, and digital infrastructure. Ratcliff joins Emerj Editorial Director Matthew DeMello to discuss how enterprise leaders can scale AI effectively by buil…

1
ACT Brief: Tech-Driven Data Strategies and Long-Term Vaccine Success 2:38

26d ago2:38

2:38

In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore how Phastar is using technology to accelerate drug development, and review Takeda’s seven-year dengue vaccine results confirming long-term efficacy and safety.By Applied Clinical Trials

1
CPG Data Challenges to Business Value with Agentic AI - with Jim Johnson of AnswerRocket 26:32

25d ago26:32

26:32

Today's guest is Jim Johnson, President at AnswerRocket. Founded in 2013, AnswerRocket builds enterprise AI agents delivering measurable outcomes for Fortune 2000 clients across consumer goods, financial services, construction, real estate, and beyond. Johnson joins Emerj Editorial Director Matthew DeMello to discuss how consumer packaged goods com…

1
Making Microsoft Copilot and ChatGPT Enterprise Work for You - with Matt Berseth and Russell Dixon of NLP Logix 31:42

26d ago31:42

31:42

Today's guests are Matt Berseth, Co-founder and CIO at NLP Logix, and Russell Dixon, Strategic Advisor at NLP Logix. NLP Logix is a fast-growing AI services firm based in Florida that serves both the public and private sectors. Berseth and Dixon join Emerj Editorial Director Matthew DeMello to discuss how enterprise leaders can successfully deploy …

1
E190: AI-Powered Women's Health: Closing the Gender Data Gap in Medical Research 33:12

26d ago33:12

33:12

For decades, medical research has been built around male data — leaving women dangerously underrepresented in clinical trials, drug development, and symptom understanding. The result? Misdiagnoses, ineffective treatments, and life-threatening blind spots in women’s healthcare. In this episode, Sonja Rincon, CEO and founder of MenoTracker, reveals h…

1
Streamlining Clinical Data to Reduce Site and Participant Burden 8:55

27d ago8:55

8:55

In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential. Th…

1
Exploring Mixed Features in Major Depressive Disorder: The Case of Gus 25:56

27d ago25:56

25:56

Today, we delve into the intricate case of mock patient, Gus, a 23-year-old male grappling with debilitating depression and psychotic symptoms. His experience includes a notable history of Wellbutrin use, which initially seemed effective but has since waned in its efficacy. Moreover, Gus reports auditory hallucinations and visual disturbances, addi…

1
Diabetes Core Update Nov 2025 27:46

27d ago27:46

27:46

This issue will review: 1. Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis - Diabetes Care 2. Orforglipron, an Oral Small-Molecule GLP-1Receptor Agonist, in Early Type 2 Diabetes – NEJM 3. Orforg…

1
How Enterprise Industrial Leaders Are Applying AI to Systemic Manufacturing Problems - with Emily Nguyen of Palantir Technologies 27:06

27d ago27:06

27:06

Today's guest is Emily Nguyen, Head of Industrials and Warp Speed at Palantir Technologies. Emily joins Emerj Editorial Director Matthew DeMello on the show to discuss the realities of AI adoption on the factory floor. Despite rapid advances in AI, many manufacturers still rely on legacy systems, siloed data, and even pen-and-paper processes. Emily…